Document is current
Any future updates will be listed below
-
Authors
Yin, Jiang-An https://orcid.org/0000-0002-2134-8693
Frick, Lukas
Scheidmann, Manuel C.
Liu, Tingting
Trevisan, Chiara https://orcid.org/0000-0002-3997-094X
Dhingra, Ashutosh
Spinelli, Anna
Wu, Yancheng https://orcid.org/0000-0003-2809-4865
Yao, Longping
Vena, Dalila Laura https://orcid.org/0009-0007-6863-7349
Knapp, Britta
Guo, Jingjing
De Cecco, Elena
Ging, Kathi
Armani, Andrea https://orcid.org/0000-0002-4765-9748
Oakeley, Edward J. https://orcid.org/0000-0001-6226-7470
Nigsch, Florian https://orcid.org/0000-0002-2919-8749
Jenzer, Joel
Haegele, Jasmin
Pikusa, Michal
Täger, Joachim
Rodriguez-Nieto, Salvador
Bouris, Vangelis
Ribeiro, Rafaela
Baroni, Federico
Bedi, Manmeet Sakshi
Berry, Scott
Losa, Marco https://orcid.org/0000-0003-3428-418X
Hornemann, Simone https://orcid.org/0000-0002-2674-9891
Kampmann, Martin
Pelkmans, Lucas
Hoepfner, Dominic
Heutink, Peter
Aguzzi, Adriano
- License Information
-
More Information
Article History
Received: 25 September 2023
Accepted: 4 October 2024
First Online: 4 December 2024
Competing interests
: J.-A.Y., L.F. and A. Aguzzi are listed as inventors on a patent (Molecular Cloning Method and Vector Therefore, WO/2023/089153) owned by the University of Zurich, whose claims are supported by the present study. L.P. has ownership interest in Sagimet Biosciences, Apricot Therapeutics and Element Biosciences. M.K. is an inventor on US Patent 11,254,933 related to CRISPRi and CRISPRa screening, serves on the Scientific Advisory Boards of Engine Biosciences, Casma Therapeutics, Cajal Neuroscience, Alector and Montara Therapeutics, and is an advisor to Modulo Bio and Recursion Therapeutics. All authors with the affiliation ‘Novartis Institutes for Biomedical Research’ are employees of Novartis Pharma AG and may own stock in the company. The other authors declare no competing interests.
